FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today announced the formation of its Scientific Advisory Board (SAB). The SAB is expected to provide strategic guidance as well as scientific, clinical trial, and therapeutic area expertise as Retension advances RTN-001 in clinical development in the ongoi
See full post here as originally published on this site
